WS #15891

From 79 msgs · 6 key-dev
Holding: newest synthesis is 9d 22h old

The market is undergoing a severe repricing cycle triggered by hotter-than-expected US CPI data (3.7% headline, 2.6% core), which has shattered hopes for a pause in Fed tightening and triggered a broad equity selloff. The Nasdaq 100 has extended losses beyond -2%, erasing approximately $1 trillion in market capitalization, while the Russell 2000 enters correction territory. The Fed Beige Book corroborates the inflationary pressure, noting robust price growth in three districts and intensifying input costs in eight, signaling that the inflation fight is far from over. Simultaneously, geopolitical risks are compounding the macro headwinds. The Iran war continues to disrupt energy markets, with India cutting gas demand due to soaring LNG spot prices and Saudi airlines scrambling to protect assets. The narrative of Middle East escalation remains the dominant geopolitical risk, creating a hostile environment for rate-sensitive growth stocks and consumer discretionary names. While the IEA previously warned of diesel shortages, the current focus has shifted to the broader demand destruction caused by high energy costs. In the technology sector, the AI infrastructure narrative is fracturing under the weight of higher rates. CoreWeave has plunged 15% as credit conditions tighten, and ASML's bullish long-term demand outlook is failing to lift the stock, suggesting the market is prioritizing near-term discounting over long-term growth. Conversely, TSMC's upcoming earnings report is being watched as a critical litmus test for the semiconductor group's health; a raise could provide a floor, but the current liquidation in chip stocks suggests extreme fragility.

Topics

Key developments

  • US CPI Hits 3.7%, Triggering Broad Market Selloff
  • CoreWeave Plunges 15% on AI Credit Concerns
  • India Cuts Gas Demand as Iran War Spikes LNG Prices
  • MTA Cuts Bond Refinancing by 40% on High Yields
  • Goldman Downgrades Carrier Global and Lennox
  • ImmunityBio Surges on FDA Approval